Want to see LEGN full AI Analyst Report?
LEGN Stock Chart & Stats
$21.17
-$0.50(-1.49%)
At close: 4:00 PM EST
$21.17
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$16.24 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)2.41M
Market Cap
$4.31B
Enterprise Value$2.90K
Total Cash (Recent Filing)$834.63M
Total Debt (Recent Filing)$389.31M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 18, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding193,439,790
10 Day Avg. Volume2,255,066
30 Day Avg. Volume2,406,264
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)4.00
Price to Sales (P/S)3.89
P/FCF Ratio-23.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.85Price Target Upside159.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.02
Revenue Forecast (FY)$1.43B
Bulls Say, Bears Say
Bulls Say
Revenue Growth / CARVYKTI SalesSustained, high-single- to double-digit growth in CARVYKTI sales and TTM revenue expansion to ~$1.14B indicate durable commercial adoption. This revenue scale supports reinvestment, improves negotiating leverage with partners, and underpins longer-term margin recovery and R&D funding capacity.
Manufacturing & Supply ReliabilityVery high manufacturing reliability is a structural competitive advantage for an autologous cell therapy developer. Consistent manufacturing and fast turnaround reduce treatment delays, enable broader community adoption and earlier-line use, and materially lower logistics risk as volume scales.
Liquidity & Manageable LeverageA strong cash position and modest leverage provide runway to complete planned IND filings, invest in manufacturing scale-up and early-stage programs, and absorb near-term losses. This balance-sheet flexibility reduces immediate refinancing pressure and supports execution of strategic initiatives.
Bears Say
Ongoing Cash Burn & LossesPersistent negative operating and free cash flow and a materially negative net margin mean the business is not yet self-funding. Continued cash burn raises reliance on equity, milestone inflows or collaboration economics, risking dilution or constrained investment if revenue or margins stall.
Gross Margin Volatility From Ramp CostsSharp quarter-to-quarter gross margin swings driven by one-time facility ramp costs highlight execution sensitivity during scale-up. If ramp expenses recur or are larger than disclosed, margin recovery and the path to company-wide profitability could be delayed and forecasting becomes more uncertain.
Clinical & Timing Risk For Label ExpansionKey label expansions and milestone triggers depend on event‑driven pivotal readouts and early-stage In Vivo data. Timing and outcome uncertainty for these trials can materially affect future revenue, milestone recognition, and strategic positioning versus bispecifics and other modalities.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $16.24 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $4.31B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 18, 2026 which is in 26 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.162.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is 0.05.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 193,439,790 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.15 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went up 10.477%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.85 (159.09% Upside)
$54.85 (159.09% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.17%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
LEGN Stock 12 Month Forecast
Average Price Target
$54.85
▲(159.09% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.15% Insiders
13.26% Mutual Funds
1.02% Other Institutional Investors
82.65% Public Companies and
Individual Investors